Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
antirheumatics/vähk
Link salvestatakse lõikelauale
Leht 1 alates 75 tulemused
Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Traditional Chinese medicine (TCM) and dendritic cells (DCs) activation/maturation One of the important approaches to successful cancer immunotherapy is generation of specific T cell responses by dendritic cells (DCs). DCs are the most potent antigen-presenting cells for naive T cells, because their
Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
SPARTACUS will have several achievable goals:
1. To show superiority of early treatment of pSpA patients with bDMARDs as compared to standard of care.
In current practice, TNFi, the predominant bDMARDs in SpA, are only reimbursed in a restricted number of indications: they can be prescribed for
Socio-economic Determinants for Acceptance and Choice of Biological Treatment
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This was a cross-sectional observational study conducted in the rheumatology clinic of National Center for Rheumatic Diseases, Kathmandu, Nepal. Patients with spondyloarthropathy (SpA) and enrolled in the cohort database from June 2015 to December 2019 were selected. Those taking any oral or
Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Over the last decades biopharmaceuticals such as agents against tumor necrosis factor (TNF), are frequently prescribed to optimize rheumatoid arthritis treatment. Although TNFi such as adalimumab, etanercept and infliximab, have improved the treatment of rheumatoid arthritis, a proportion of
Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The tumor necrosis factor inhibitors(TNFi) like etanercept(ETN) has been always recommended as the primary treatment option for active AS. But when sustained applied in daily clinical practices, it is unaffordable for patients in developing countries in most cases due to the high expense of TNFi. On
Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Background:
Uveitis is a potentially blinding complication of juvenile idiopathic arthritis (JIA). Treatment remains a substantial challenge, even though the use of tumor necrosis factor (TNF)-α-antagonists has improved visual outcomes substantially. Among these agents, adalimumab has been recently
Advanced Therapeutics in Rheumatoid Arthritis (RA)
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Conventional therapies for Rheumatoid Arthritis (RA) treatment include nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) selective inhibitors, corticosteroids and disease modifying anti-rheumatic drugs (DMARDs). These therapies are often partially effective.
For those patients,
Metformin Use in Rheumatoid Arthritis
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Abatacept and the Risk of Cancer: a Case Non-case Analysis in VigiBase
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
A case non-case study using Vigibase®, the World Health Organization Global Individual Case Safety Reports (ICSRs) database which includes more than 18 million reports forwarded to the WHO Uppsala Monitoring Center by national pharmacovigilance systems from over 130 countries around the world since
Cognitive Behavioural Therapy for Insomnia on Sleep in Rheumatoid Arthritis.
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Introduction:
More than half of patients with rheumatoid arthritis has concomitant insomnia. Insomnia may modify pain, fatigue, quality of life and comorbidities which many patients struggle with. To address this issue, a nurse led sleep outpatient clinic was established in 2015 at the Center for
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Arm 1: Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard practice in these PsA clinics following current international recommendations[11] and National requirements for the prescription of biologic therapy[19-22]. Whilst physician discretion
PsA Secukinumab XCT Structural Progression Study
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Psoriatic arthritis (PsA) is a chronic inflammatory joint disease associated with psoriasis. PsA is associated with distinctive clinical features including changes in skin and nails, peripheral arthritis, axial disease, dactylitis and enthesitis. Synovial inflammation in peripheral joints is the
The Immunogenicity and Safety of Zostavax® in Rheumatoid Arthritis Patients Using Abatacept
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Recently, a live-attenuated vaccine (Zostavax®, Merck) to prevent herpes zoster (HZ) has been developed and approved for use among individuals age 50 years or older, regardless of previous HZ or varicella history. In a pivotal study of 38,456 older adults led by Dr. Michael Oxman (a co-investigator
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The study duration per patient is expected to be approximately 32 weeks, with up to 4-week screening, 24 weeks treatment, and 2-4 weeks post-treatment observations.
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
